Renewal Bio, a newly formed biotechnology company focused on infertility and longevity, today announced it has acquired an exclusive license from Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, to a newly developed synthetic embryo technology. The technology was spearheaded by Prof. Jacob Hanna, Ph.D., M.D., as recently published in Cell, and builds on his research published in Nature last year. Renewal Bio plans to develop a bio platform that combines biology, hardware, and software to drive advancements and develop therapies for infertility, genetic diseases, lab-grown organs, and blood system rejuvenation.

The Problem: Humanity is Getting Older and Sicker

Since the turn of the century, developed nations have seen a clear trend: declining birth rates and fast aging populations. With significant socioeconomic implications, this trend threatens to upend health systems, retirement programs, and workforces across the globe. At the beginning of life, this is shown by a 5-10% increase in infertility treatments by U.S. couples each year. Towards the end of life, these issues are manifesting in fast-aging populations that balloon healthcare costs. In the U.S., the aging population is driving national health expenditures to increase at a rate of 5.5% per year, and are expected to reach more than $6 trillion annually by 2027.

The Solution: A Bio Platform to Renew Humanity

To solve these complex and compounding issues, Renewal Bio aims to make humanity younger and healthier by leveraging the power of the new stem cell technology. The technology can be applied to a wide variety of human ailments including infertility, genetic diseases, and longevity.

Renewal Bio's founding team includes:

• Omri Amirav Drory, Ph.D. - Interim CEO - a two-time scientist Founder behind Genome Compiler, software platform for genetic engineers and molecular and synthetic biologists which was acquired by Twist Biosciences. He is also a General Partner at NFX Bio, a leading life science venture capital firm.
  
• Jacob Hanna, Ph.D., M.D. - Chief Scientific Advisor - Professor of Stem Cell Biology in the Department of Molecular Genetics at the Weizmann Institute of Science in Israel. Prof. Hanna is a leading researcher in the fields of pluripotent stem cell biology, early embryonic development, and modeling human diseases.
  

Anyone interested in joining the company's mission of making humanity younger and healthier can learn more at renewal.bio.

About Renewal Bio

Founded in 2022, Renewal Bio mission is to renew humanity - making us younger and healthier. The company was founded by Omri Amirav Drory and Jacob Hanna to develop therapies ranging from infertility treatments to lab-grown organs using novel stem cell technology developed at the Weizmann Institute of Science. Learn more at renewal.bio.

About Yeda

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda currently manages approximately 500 unique patent families and has generated the highest income per researcher compared to any other academic technology transfer operation worldwide. Through the years, Yeda has contributed to the commercialization of a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad®, Erbitux®, Vectibix®, Protrazza®, Humira®, and the CAR-T cancer therapy Yescarta®. For more information, visit www.yedarnd.com/.

About the Weizmann Institute of Science

The Weizmann Institute of Science in Israel is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, Weizmann Institute's scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics and particle physics, and are tackling diseases such as cancer, while also addressing climate change through environmental, ocean, and plant sciences.

— WebWireID292455 —